<DOC>
	<DOCNO>NCT00916747</DOCNO>
	<brief_summary>Hutchinson-Gilford Progeria Syndrome ( Progeria ) rare autosomal disease result premature death median age 13 year due cardiovascular cerebralvascular compromise . The mutation disease identify result mutant form lamin A de-farnesylated . This study evaluate combination pravastain ( statin ) , lonafarnib ( farnesyltransferase inhibitor ) zoledronic acid ( bisphosphonate ) open label phase II efficacy trial child Progeria . These agent target farnesylation pathway different point . Patients genetically confirm progeria eligible protocol . Treatment initiate 24 month duration . Clinical biologic parameter examine assess response .</brief_summary>
	<brief_title>Study Zoledronic Acid , Pravastatin , Lonafarnib Patients With Progeria</brief_title>
	<detailed_description />
	<mesh_term>Progeria</mesh_term>
	<mesh_term>Pravastatin</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Genetic Diagnosis : All patient must confirmatory mutational analysis show mutation lamin A gene . Clinical Diagnosis : Patients must display clinical sign progeria per clinical trial team . Travel : Patients must willing able come Boston appropriate study examination initiation study month 6 , 12 , 18 24 study . Patient must adequate organ marrow function define follow parameter : Blood : APC ( ANC + band + monocyte = APC ) &gt; 1,000/microliters , Platelets &gt; 75,000/microliters ( transfusion independent ) ; Hemoglobin &gt; 9g/dl . Renal : creatinine Less equal 1.5 time normal age GFR &gt; 70 ml/min/1.73m2 . Hepatic : bilirubin Less equal 1.5 x upper limit normal age ; SGPT ( ALT ) &lt; SGOT ( AST ) &lt; 5 x normal range age . PT/PTT : PT/PTT &lt; 120 % upper limit normal OR PI approval No overt renal , hepatic , pulmonary disease immune dysfunction . 25hydroxyvitamin D â‰¥ 20 ng/ml within 4 week bisphosphonate infusion . Signed informed consent accord institutional guideline must obtain patient must begin therapy within twenty eight ( 28 ) day . Other drug use protocol , drug target treat Progeria exclude . Drugs treat symptom Progeria permit . Patients must take medication significantly affect metabolism lonafarnib time start lonafarnib Patient must uncontrolled infection . Subjects know suspected hypersensitivity excipients include formulation treat . Patients must pregnant breastfeeding . Female patient childbearing potential must negative serum urine pregnancy test . Male female patient reproductive potential must agree use medically accept form birth control study 10 week treatment . It permissible female patient take oral contraceptive hormonal method receive treatment lonafarnib .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Progeria</keyword>
</DOC>